Latest Dilution News

Transurban Group reveals modest participation in its latest Distribution Reinvestment Plan, with new securities priced at $13.4692 ahead of the August payment date.

Arizona Lithium has secured regulatory approval for Phase 1 production at its Prairie Lithium Project in Saskatchewan and raised $4.25 million through an oversubscribed share purchase plan, marking key milestones toward commercial lithium extraction.

SportsHero Limited has raised $1.65 million through a private placement to boost its e-sports gaming and community platforms, targeting new partnerships and market growth in Southeast Asia.

Vital Metals’ latest Scoping Study for its Tardiff deposit in Canada reveals strong economic potential, underpinning an 11-year mine life with significant rare earth and niobium production. The company plans to advance to a Prefeasibility Study by the end of 2026, aiming to optimize recoveries and expand resources.

Core Lithium has repositioned its Finniss Lithium Project as a low-cost underground operation with a 20-year mine life, slashing operating costs by a third and boosting production capacity. The company is advancing strategic funding while unlocking flexibility through a key offtake agreement termination.

Neurizon Therapeutics has made significant strides in developing its lead ALS drug candidate NUZ-001, unveiling a new liquid formulation and submitting a key regulatory response to the FDA. Clinical and preclinical data bolster hopes for broader neurodegenerative applications.

Neurizon Therapeutics has secured a $1.5 million loan against its expected 2025 R&D tax rebate, boosting liquidity without diluting shareholders. This strategic move supports ongoing development of its neurodegenerative disease treatments.

Actinogen Medical has reached a key milestone in its XanaMIA phase 2b/3 Alzheimer’s trial with over 100 participants enrolled, setting the stage for an interim analysis in January 2026. The company also secured a $13.8 million non-dilutive R&D funding facility to support ongoing development.

Locate Technologies reported a 5% revenue increase for FY25, driven by strong growth in its Locate2u platform, while Zoom2u faced revenue headwinds. The company also expanded its Bitcoin holdings and raised $2.5 million in capital.

Noxopharm has initiated its HERACLES clinical trial for SOF-SKN, marking a key milestone for its Sofra platform, while deepening partnerships and actively seeking new funding to sustain development.

Lefroy Exploration has advanced its Lucky Strike Gold Deposit project through robust near-surface drilling results, a new toll milling agreement, and a $2.5 million funding facility, setting the stage for mining operations in early 2026.

EMVision Medical Devices reports strong progress in its pivotal trial for the emu™ bedside brain scanner and successful aeromedical testing of its First Responder device, backed by a $5 million government grant and $10.5 million in cash reserves.